Methylcobalamin (MCB or MeB12) is a cobalamin used in the treatment of peripheral neuropathy, diabetic neuropathy, and as a preliminary treatment for amyotrophic lateral sclerosis. It is a form of vitamin B12 and differs from cyanocobalamin in that the cyanide is replaced by a methyl group. Methylcobalamin features an octahedral cobalt (III) centre. Methylcobalamin can be obtained as bright red crystals. Literature survey reveals that HPLC & simple UV spectrophotometric methods have been established for the estimation of MCB in bulk and tablet dosage form. The aim of present study was to establish a method for estimation of MCB in tablet dosage form by using first order derivative spectroscopy (method A) & area under curve methods (method B & C). Absorption minima in first order derivative spectra was found to be 384 nm (method-A) and area under curve was measured from 260-275 nm for zero order spectra (method-B) and 310-360 nm for first order spectra (method-C), the drug followed a linear relationship in the range of 10-40 μg/ml while the correlation coefficient was at 1.000, 0.999 and 0.999 respectively. The recovery was 99.52% ±0.56 (method-A) and the coefficient of variance for intraday and interday was found to be less than 2%, LOD and LOQ for this method was found 01 μg/ml and 05 μg/ml (method-B) respectively. This method is found suitable for day to day analysis of MCB in tablet dosage form.
Loading....